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Interstitial lung disease (ILD) comprises a heterogeneous group of diffuse parenchymal 
lung processes with overlapping clinical, radiographic, and histopathologic features. 
Among the most common and deadly ILDs are idiopathic pulmonary fibrosis (IPF) and 
chronic hypersensitivity pneumonitis (CHP). As the name implies, the cause of IPF 
remains elusive, but a variety of genetic and infectious risk factors have been identified. 
CHP results from chronic inhalation of an organic antigen, usually of avian or mold 
origin, and may occur in patients with a genetic predisposition. While IPF is treated 
with anti-fibrotic compounds, CHP is generally treated by suppression of the immune 
system and elimination of the causative antigen. Despite advances in our understand-
ing of IPF and CHP, there exists substantial variability in the diagnosis and treatment 
of these disease processes. Furthermore, IPF and CHP natural history and treatment 
response remain far from uniform, leaving it unclear which patients derive the most ben-
efit from disease-specific therapy. While clinical prediction models have improved our 
understanding of outcome risk in patients with various forms of ILD, recent advances 
in genomic technology provides a valuable opportunity to begin understanding the 
basis for outcome variability. Such advances will ultimately allow for the incorporation 
of genomic markers into risk stratification and clinical decision-making. In this piece, we 
highlight recent advances in our understanding of the genomic factors that influence 
susceptibility and outcome risk among patients with IPF and CHP. Genomic modalities 
used to identify these genomic markers include genome-wide association studies, 
analyses of gene expression, drug–gene interaction testing, telomere length determi-
nation, telomerase mutation analysis, and studies of the lung microbiome. We then 
identify gaps in knowledge that should be addressed to help facilitate the incorporation 
of these genomic technologies into ILD clinical practice.
Keywords: idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, interstitial lung disease, idiopathic 
interstitial pneumonia, genomics
iNTRODUCTiON
The interstitial lung diseases (ILDs) are comprised of a heterogeneous group of diffuse parenchymal 
lung processes with overlapping clinical, radiographic, and histopathologic features (1). Among the 
most common ILDs are idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumo-
nitis (CHP). IPF is progressive fibrosing interstitial pneumonia of unclear etiology with recently 
identified genetic and microbial risk factors (2–7). CHP results from an inappropriate immunologic 
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response to chronic inhalation of organic antigen, usually of 
avian or mold origin, and results in pulmonary fibrosis after 
prolonged exposure (8). Like IPF, one’s genetic makeup likely 
influences CHP susceptibility (9–11).
Idiopathic pulmonary fibrosis is now treated with compounds 
targeting fibrotic mediators after phase III clinical trials demon-
strated efficacy in slowing pulmonary function decline (12–14). 
Prospective treatment data for CHP is lacking, but management 
is generally geared toward attempted removal of the causative 
antigen, along with variable suppression of the immune system, 
as this has been associated with stability in pulmonary function 
(15, 16). While these disease-specific treatment approaches 
appear to favorably impact disease course, there remains substan-
tial variability in outcomes within IPF and CHP. Recent advances 
in genomic technologies have provided a valuable opportunity to 
begin understanding the basis for this outcome variability.
In this review, we highlight recently identified genomic factors 
influencing susceptibility and outcomes of patients with IPF and 
CHP. These include single-nucleotide polymorphisms (SNPs) 
identified by targeted sequencing and genome-wide association 
studies (GWAS), gene expression profiling, telomere length 
testing, and lung microbiome bacterial DNA profiling. We then 
identify gaps in knowledge that should be addressed to help 
facilitate the incorporation of these genomic technologies into 
ILD clinical practice.
Gene Polymorphisms
Three GWAS have been performed in patients with IPF to date, 
which identified SNPs within a number of loci to be associated 
with IPF susceptibility (2, 3, 6). Among the variants identified by 
this approach were several on the short arm of chromosome 11, 
including a SNP in the promoter of MUC5B (rs35705950) and 
an intronic SNP near TOLLIP (rs5743890). MUC5B encodes one 
of several mucin-producing genes, which facilitate airway clear-
ance and function to maintain immune homeostasis (5, 17, 18). 
TOLLIP encodes toll-interacting protein, which inhibits toll-like 
receptor signaling and acts as a critical mediator of airway host 
defense (17, 19–22). The MUC5B promoter SNP increases the 
risk of developing IPF by roughly threefold, while the intronic 
TOLLIP SNP reduces the risk by about 70%. The MUC5B pro-
moter polymorphism has also been shown to increase the risk 
of developing interstitial lung abnormalities (ILA) among the 
general population (23). While the proportion of patients with an 
ILA that ultimately develop IPF remains unknown, this variant 
does appear to increase risk of progressive disease (24).
Besides influencing IPF susceptibility, SNPs within MUC5B 
and TOLLIP may also have prognostic significance. While 
increasing IPF susceptibility risk, the MUC5B promoter SNP is 
paradoxically associated with a twofold decrease in mortality 
risk (25). A similar finding is observed with the intronic TOLLIP 
SNP, which is associated with a 65% increase in mortality risk, 
despite reducing the risk of developing IPF (6). A recent phar-
macogenetic investigation sought to determine whether relevant 
variants in TOLLIP and MUC5B may influence IPF treatment 
response. Using paired clinical and genotype data from patients 
enrolled in the previously completed effectiveness of Prednisone, 
Azathioprine, and N-Acetylcysteine in Patients with Idiopathic 
Pulmonary Fibrosis (PANTHER) trial (26, 27), investigators 
showed that an exonic SNP within TOLLIP (rs3750920) was 
associated with a favorable responsive to N-acetylcysteine (NAC) 
(28). Compared to placebo, those with the TT genotype at this 
SNP treated with NAC had a significantly reduced composite 
endpoint risk, including death, hospitalization, and forced vital 
capacity decline (Figure 1). Those with the CC genotype treated 
with NAC had a trend toward harm when compared to placebo 
and outcomes were similar in those with the CT genotype. 
Approximately 25% of patients with IPF carry both copies of this 
polymorphism, suggesting that NAC may benefit a large minority 
of IPF patients if these findings are replicated in a prospective 
clinical trial.
No GWAS have been performed in patients with CHP to date, 
but studies employing targeted genotyping have identified gene 
variants linked to disease susceptibility and outcomes. Camarena 
and colleagues conducted targeted genotyping of SNPs within the 
major histocompatibility complex (MHC) II region and found 
that SNPs within HLA-DRB1 were disproportionately present 
in patients with avian antigen-associated CHP compared to 
control subjects (11). Subsequent studies by this group implicated 
polymorphisms in transporter-associated antigen processing 
genes and tumor necrosis factor as potential risk factors for 
CHP susceptibility (29). Ley and colleagues recently showed the 
MUC5B promoter polymorphism linked to IPF susceptibility to 
be present in a significantly higher proportion of patients with 
CHP compared to healthy controls (30). However, as opposed to 
patients with IPF, the MUC5B promoter SNP was associated with 
increased mortality risk in those with CHP, though the strength 
of this association varied across cohorts. These investigators also 
assessed the intronic TOLLIP SNP previously linked to IPF, but 
found no association with either susceptibility or survival in 
those with CHP.
Gene expression
While GWAS have identified gene polymorphisms that may 
influence IPF susceptibility, transcriptomic analyses of RNA 
isolated from lung tissue and peripheral blood have shed impor-
tant light on gene expression pathways involved in IPF and CHP 
pathogenesis and outcomes. Selman and colleagues conducted a 
microarray analysis of RNA obtained from lung tissue in patients 
with IPF and CHP to determine whether gene expression profiles 
could differentiate these disease processes. These investigators 
showed that while patients with IPF had upregulation of genes 
involved in tissue remodeling, apoptosis and fibroblast signal-
ing, those with CHP displayed upregulation of genes critical 
to immunologic function, including those T cell signaling and 
others related to MHC function (9).
Subsequent transcriptomic investigations using lung and 
peripheral blood specimens from patients with IPF supported 
the role of genes involved in alveolar epithelial injury and 
remodeling in IPF pathogenesis (31, 32). Yang and colleagues 
showed that alpha defensin signaling in the peripheral blood 
may play a role in disease progression, as differential expression 
of this and other associated pathways characterized disease 
severity in these patients (32). Selman and colleagues showed 
that compared to IPF patients with relatively stable disease, lung 
FiGURe 1 | Composite endpoint-free survival between N-acetylcysteine (NAC) and placebo groups after stratification by rs3750920 (TOLLIP) genotype. In those 
with a CC genotype (A), NAC therapy is associated with worse survival than placebo [Plogrank = 0.01; hazard ratio (HR), 3.23; 95% confidence interval (CI), 
0.79–13.16; P = 0.10]. In those with a CT genotype (B), survival is similar between groups (Plogrank = 0.82; HR 0.76; 95% CI 0.27–2.19; P = 0.62). In those with a TT 
genotype (C), NAC therapy is associated with improved survival compared with placebo (Plogrank = 0.06; HR 0.14; 95% CI 0.02–0.83; P = 0.03). Multivariable Cox 
regression models adjusted for age, sex, forced vital capacity (percentage predicted), and diffusion capacity of the lung for carbon monoxide (percentage predicted) 
at time of study enrollment. Reprinted from Ref. (28) with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society.
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tissue of patients with accelerated disease progression displayed 
an overexpression of genes involved in oxidative stress and 
fibroblast proliferation (31). These data suggest that unique 
molecular phenotypes exist that may help better predict disease 
trajectory.
In addition to differentiating IPF from other forms of ILD, 
investigators have utilized transcriptomic analysis to develop a 
peripheral blood-based genomic prediction tool to predict IPF 
survival. Using a two-stage, multi-center derivation and valida-
tion approach, Herazo-Maya and colleagues identified a gene 
signature composed of 52 differentially expressed genes could 
effectively categorize patients with high versus low mortality 
risk over a 4-year follow-up period (33). This gene signature had 
similar test performance characteristics as a validated clinical 
prediction model (34) and significantly improved the clinical 
model when the gene signature was incorporated. These inves-
tigators then validated this 52-gene signature across 6 centers 
in the United States and Europe (Figure  2) and showed that 
initiation of anti-fibrotic therapy was associated with favorable 
modulation of the gene signature (35). Many of the differentially 
expressed genes identified by this approach are critical to immu-
nologic activation, suggesting that dysregulation of the immune 
response may contribute to IPF progression.
Telomere Length
Studying large families with multiple affected members led to the 
discovery of multiple genes associated with monogenetic forms 
of familial pulmonary fibrosis (FPF) and improved our under-
standing of the genetic underpinnings of ILD. To date, there have 
been seven telomere-related genes that have been implicated in 
adult-onset FPF (TERT, TERC, RTEL1, PARN, NAF1, TINF2, 
DKC1) (36–43). Pathogenic variants in telomere-related genes 
are associated with extremely short age-adjusted telomere length 
that predispose to multisystem organ dysfunction, including 
pulmonary fibrosis, liver dysfunction, and bone marrow failure 
(44, 45).
FiGURe 2 | 52-gene risk profiles and outcomes independent of demographic and clinical variables. (A) Pooled data analysis comparing high-risk profile 
patients with low-risk profile patients from all cohorts. Color scale is shown adjacent to heat maps in log-based two scale. Mortality (B) and transplant-free 
survival (C) differ between high-risk and low-risk patients from all cohorts after adjusting for age, sex, FVC%, and immunosuppressive therapy. AUC of 
time-dependent receiver operating characteristic analysis for mortality (D) and transplant-free survival (e) based on the GAP index alone or the G-GAP index 
in all patients. Abbreviations: BWH–HMS, Brigham and Women’s Hospital–Harvard Medical School; FVC, forced vital capacity; AUC, area under the curve; 
GAP, Gender, Age, and Physiology; G-GAP, GAP and genomic; HR, hazard ratio. Reprinted from Ref. (35) with permission from Elsevier. Copyright © 2017 
Elsevier.
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FiGURe 3 | Telomere length is associated with prognosis in idiopathic pulmonary fibrosis (IPF), chronic hypersensitivity pneumonitis (CHP), and telomere-related 
familial pulmonary fibrosis (FPF). Telomere lengths for healthy controls follow a normal distribution (dashed line). Mean telomere length for CHP, IPF, and telomere-
related FPF cohorts are shorter than healthy controls (49, 50). Overall prognosis and mean telomere length follow similar pattern across diagnoses 
(CHP > IPF > telomere-related FPF); and shorter individual telomere length is associated with worse prognosis in patients with IPF and CHP (49, 30). The presence 
of a rare variant in the telomere-related genes (TERT, TERC, PARN, or RTEL1) is associated with extremely short telomere length and poor prognosis (37, 48).
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Telomeres, or the ends of chromosomes, solve the end 
replication problem and prevent the activation of DNA dam-
age pathways. Telomere-related pathogenic variants are found 
in ~30% of all FPF kindred (36, 37, 46–48); TERT is the 
most commonly affected gene and accounts for ~20% of FPF 
(36, 38). The inheritance of a telomere-related pathogenic 
variant confers substantial risk for ILD development; however, 
other factors such as age, gender, environmental exposures, and 
telomere length also contribute to the variability in penetrance 
(36, 46–48). Unfortunately, there is poor genotype-ILD pheno-
type correlation in individuals with telomere-related pathogenic 
variants. While IPF is the most common clinical diagnosis 
among these FPF kindred, it accounts for less than half of cases; 
the other portion of FPF includes ILD of both known (CHP and 
connective tissue disease-associated ILD) and unknown causes 
(idiopathic nonspecific interstitial pneumonia and idiopathic 
pleuroparenchymal fibroelastosis) (48). Interestingly, the pres-
ence of a telomere-related rare variant in TERT, TERC, PARN, 
or RTEL1 is associated with rapid disease progression and poor 
survival regardless of the diagnosis (48). This finding implies that 
the presence of a pathogenic variant in a telomere-related gene 
trumps the clinical diagnosis in terms of disease behavior and 
overall prognosis. This also suggests that telomere dysfunction 
not only predisposes to disease development but may also be 
involved in disease progression and fibrosis propagation.
Short age-adjusted telomere lengths are found more com-
monly in ILD patients than rare genetic variants (46) and are 
present across a wide variety of ILDs, including IPF and CHP 
(49, 50). Short telomere length is relatively common in both of 
these diseases, 23–50% of patients with sporadic IPF and 24% of 
CHP patients have age-adjusted telomere length less than 10th 
percentile (46, 51, 30). Similar to telomere-related rare variants, 
the presence of short telomere length is associated with poor 
prognosis in patients with IPF and CHP (Figure 3).
The association between short telomere length and survival 
in IPF has been replicated in multiple independent cohorts 
(49, 52), and recently this association was expanded to patients 
with CHP (30). There is significant overlap between the clinical, 
radiographic, and histopathologic features of IPF and CHP. 
Telomere length may be partly responsible for this overlap since 
short age-adjusted telomere length is associated with radiographic 
and histopathologic “IPF-like features” including honeycombing, 
temporal heterogeneity, and fibroblastic foci in patients with 
well characterized CHP (30). Further studies are needed across 
other subtypes of ILD, such as autoimmune-mediated ILD, to 
determine if short telomere length represents a robust predictor 
of prognosis or disease progression across clinical diagnoses. If 
so, this would argue that molecular classification, specifically 
with telomere length, could improve our ability to predict disease 
course in a wide variety of ILD subtypes.
Lung Microbiome
Genetic susceptibility alone is not enough to develop pulmonary 
fibrosis and an environmental trigger is likely required to initi-
ate the fibrotic cascade. Many environmental factors associated 
with IPF susceptibility have been identified, but historically most 
research of infective agents has focused on the role of viruses in 
the pathogenesis and progression of IPF (53). This was in part 
due to the incorrectly held mantra that the lungs were sterile 
outside of times of clinical infection and also due to the limited 
tools available in our armamentarium; almost 70% of mucosal 
bacteria cannot be cultured (54).
Molecular, culture independent, microbiology has benefited 
from the explosion of sequencing technologies in the past decade, 
which have transformed the microbial ecology landscape. High 
throughput large-scale studies relying on genetic identification 
of the bacterial housekeeping 16S-rRNA gene can now identify 
bacterial species that were previously unable to be cultured. The 
epithelial surfaces of the respiratory tract, previously thought 
to be sterile, have been shown using these culture-independent 
techniques to accommodate dynamic microbial communities 
in health and disease (55). These communities are surprisingly 
FiGURe 4 | Kaplan–Meier curves for time until death. Subjects with 
idiopathic pulmonary fibrosis (IPF) in the top tertile with the highest bacterial 
load (16S copy number per mL of bronchoalveolar lavage) (depicted by the 
large dashed line) were at increased risk of mortality compared to IPF 
subjects in the tertile with the lowest bacterial burden (depicted by a solid 
line) (hazard ratio 4.59) (95% confidence interval, 1.05–20). Reprinted from 
Ref. (5) with permission of the American Thoracic Society. Copyright © 2016 
American Thoracic Society.
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stable in healthy individuals (55). In disease, this normal har-
mony is disrupted with distinct bacterial communities seen in 
asthma, COPD, bronchiectasis, and cystic fibrosis (55–57). In 
recent years, we have come to understand these communities are 
also altered in pulmonary fibrosis (58, 59).
The first application of a culture-independent molecular 
technique in ILD studied the microbiome in bronchoalveolar 
lavage (BAL) from patients diagnosed with a variety of idiopathic 
interstitial pneumonias using 16S-rRNA gene PCR and degen-
erating gel electrophoresis (60). This was followed by a study 
investigating the upper and lower respiratory tract microbiota 
in a group of patients with ILD compared to healthy controls 
(61). These initial studies demonstrated the presence of bacte-
rial DNA in the lower airways of patients with ILD, but revealed 
no significant differences in the microbiome between these 
patients and healthy controls. The first study to employ these 
techniques to study the microbiome in fibrotic lung disease on a 
large scale was undertaken as part of the Correlating Outcomes 
with biochemical Markers to Estimate Time-progression in IPF 
(COMET) study (4). A subset of individuals enrolled in COMET 
underwent BAL at time of enrollment, which was analyzed for 
association between microbiome indices and disease outcomes. 
Investigators identified an association between disease progres-
sion and the relative abundance of two specific Steptococcus and 
Staphylococcus OTUs. By dichotomizing patients into cohorts 
with high and low numbers of these bacterial OTUs, these authors 
demonstrated clear differences in survival. Despite this obser-
vation, however, few patients had bacterial levels above the 
statistical significance threshold, suggesting they alone did not 
explain disease progression (62). The retrospective nature of this 
investigation, along with lack of control subjects, limited the 
conclusions that could be drawn.
A subsequent prospective study of the lung microbiome 
compared IPF cases to healthy control subjects and controls 
with COPD, allowing for direct compassions between health 
and disease (5). This investigation demonstrated higher numbers 
of Veillonella, Neisseria, Streptococcus, and Haemophilus spp. 
in patients with IPF compared to controls. The most striking 
differences, however, were observed in the bacterial burden, 
which was increased twofold in IPF patients compared to control 
subjects. Within the IPF cohort, bacterial burden correlated with 
disease progression. When stratifying the cohort by this metric, 
the authors demonstrated a clear increase in mortality risk with 
increasing bacterial burden (Figure 4).
These authors also showed few differences in the microbiome 
between IPF subjects with progressive or stable disease, sug-
gesting bacterial load itself might be more important in driving 
disease progression. The authors hypothesized a mechanistic 
link between host and environment and demonstrated an 
association with bacterial burden and the MUC5B promoter 
polymorphism, with individuals carrying the minor allele of this 
SNP having a lower bacterial burden. Driven by these tantaliz-
ing interactions between host and environment, authors of both 
microbiome studies have attempted to advance the studies of the 
lung microbiome from merely descriptive and observational to 
functional (63, 64). Integrating microbial data with peripheral 
blood transcriptome data demonstrates an association between 
the microbiome and upregulation of genes involved in host 
defense and bacterial clearance. Indeed, in subjects in the 
COMET study patients with IPF and a downregulated peripheral 
immune response had higher bacterial loads of Streptococcus and 
Pseudomonas and worse survival.
GAPS iN KNOwLeDGe AND POTeNTiAL 
CLiNiCAL APPLiCATiONS
While some SNPs associated with IPF susceptibility, notably 
those within MUC5B and TOLLIP, influence both susceptibility 
and mortality risk, few others have demonstrated significant 
outcome association (6, 28). Given the substantial heterogeneity 
in IPF natural history (31, 65), it stands to reason that genomic 
factors influencing IPF susceptibility may be independent of 
those influencing IPF survival. The aforementioned GWAS 
were designed to identify SNPs disproportionately present in 
patients with IPF relative to healthy controls. A case-only GWAS 
specifically designed to identify SNPs linked to IPF survival has 
the potential to identify novel genes involved in IPF progression 
and may improve upon current outcome prediction models for 
patients with IPF and other forms of fibrotic ILD (34, 66).
The development of a transcriptomic signature to predict 
mortality has greatly improved our understanding of IPF patho-
biology. Now that IPF has two currently approved therapies, it 
will be important to assess the test performance characteristics 
of this signature in those treated with prolonged anti-fibrotic 
therapy and in those without prior exposure to immunosuppres-
sive therapy, as was common practice prior to completion of the 
PANTHER trial (27). In addition, the use of this gene signature 
to predict biologic responsiveness to anti-fibrotic therapy holds 
great promise as the field moves toward an era of personalized 
medicine. While mortality remains the most important endpoint 
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for patients and clinicians alike, the development of additional 
transcriptomic signatures to predict other clinically relevant 
endpoints, such as pulmonary function decline, has the potential 
to guide clinical trial design through enrichment of clinical trial 
cohorts with patients at high risk for meeting the trial primary 
endpoint.
The presence of telomere-related rare variants or short tel-
omere length predispose to rapid disease progression in both IPF 
and CHP, however, there is very little data regarding response 
to specific treatments. The therapeutic strategies for IPF and 
CHP differ substantially. Immune suppression is often employed 
for patients with CHP and progressive disease, while immuno-
suppression is detrimental in IPF (27). To our knowledge, the 
safety or efficacy of immunosuppression in patients with short 
telomeres and ILD has not been systematically tested. However, 
small case series of patients with rare variants in TERT and 
TERC suggest that immunosuppression after lung transplant for 
ILD may be associated with high rates of side effects including 
bone marrow failure, liver toxicity, and infections (67–69). This 
raises the question of safety and tolerability of this therapeutic 
strategy for patients with short telomere length across a wide 
variety of ILDs that are often treated with immune suppression. 
Anti-fibrotic medications, including pirfenidone and nintedanib, 
are effective at slowing lung function decline in patients with IPF 
(12–14), but their effectiveness in CHP is unknown. Pirfenidone 
was well tolerated in a small cohort of TERT carriers (70) but 
larger studies are needed to determine efficacy in patients with 
telomere dysfunction.
Idiopathic pulmonary fibrosis is characterized by a distinct 
respiratory microbiome, with a higher bacterial burden than 
in health. This is further disturbed during exacerbations of 
disease (71). Despite advances in our understanding of how the 
microbiome may influence disease susceptibility and progres-
sion, a causal, mechanistic link to these observations has yet to 
be delineated. Additionally a number of technical challenges 
remain for studies of the lung microbiome, and future work 
will need to address these (72, 73). The role of the microbiome 
in treatment response also remains unclearly defined. Two 
clinical trials assessing the efficacy of antibiotic therapy for 
patients with IPF—The Efficacy and Mechanism Evaluation 
of Treating Idiopathic Pulmonary fibrosis with the Addition 
of Co-trimoxazole (ISRCTN17464641) and Study of Clinical 
Efficacy of Antimicrobial Therapy Strategy Using Pragmatic 
Design in Idiopathic Pulmonary Fibrosis (CleanUp-IPF) 
(NCT02759120)—are currently enrolling. These trials will not 
only assess how co-trimoxazole (or doxycycline) therapy impact 
relevant IPF outcomes but also will provide the opportunity to 
study how the lung microbiome may be altered by these therapies.
The majority of genomic data generated to date has been in 
patients with IPF, leaving CHP ripe for similar investigation. 
However, standardization of diagnostic criteria through inter-
national consensus is first needed. Once that occurs, GWAS 
to identify SNPs linked to disease susceptibility and survival 
would advance our understanding of disease underpinnings and 
potentially identify novel therapeutic targets for this devastat-
ing disease without proven therapy. In addition, determining 
whether outcome-related transcriptomic signatures derived in 
patients with IPF informs outcomes in patients with CHP will 
be of immense clinical value. Finally, determining whether the 
microbiota makeup of patients with CHP influences disease 
susceptibility and outcomes has the potential to guide therapy 
in these patients.
CONCLUSiON
In this review, we highlight the most developed genomic technol-
ogies informing susceptibility and outcome risk in patients with 
IPF and CHP. There remain critical questions to be answered to 
characterize the extent to which these technologies will improve 
risk stratification. In addition, a cost benefit analysis will be nec-
essary to determine whether individual technologies make sense 
from a cost utilization perspective. The field of ILD has advanced 
rapidly over the last 10 years and will continue to do so into the 
foreseeable future. Clinical genetics represents the logical next 
step for the field and holds great potential to be a cornerstone of 
personalized medicine in the field.
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